HK Stock Market Move | CSTONE PHARMA-B (02616) rises by more than 9%, included in the FTSE China Small Cap Stock Index, rapid progress in the clinical research of three anti-tumor drug candidates.

CSTONE PHARMA-B (02616) rose by over 9%, reaching 9.18% as of press time, at 7.02 Hong Kong dollars, with a turnover of 70.8136 million Hong Kong dollars. On the news front, according to the semi-annual review and adjustment results of the FTSE Global Equity Index Series (FTSE GEIS) released by the global authoritative index compilation agency FTSE Russell, Chistone Pharma has successfully been included in the FTSE China Small Cap Index. The relevant adjustments will officially take effect after the market closes on March 20, 2026. Guoyuan International pointed out that the company's PD-1/VEGF/CTLA-4 triple antibody has excellent safety and efficacy data, and is currently conducting a global multicenter phase II clinical study. A total of 200 patients have already been enrolled, and with the gradual release of clinical data starting in March of this year, it is expected to achieve significant results.